Business UpdateJul 23, 2026, 06:08 AM
Innate Pharma to Participate in Bladder Cancer Panel at BTIG Conference
AI Summary
Innate Pharma SA announced its participation in a panel discussion titled 'Changing Treatment Landscape in Bladder Cancer' at the BTIG Virtual Biotechnology Conference on July 28, 2026. The company, a clinical-stage biotechnology firm, specializes in developing immunotherapies for cancer patients, leveraging its expertise in antibody-engineering and innovative target identification. Its pipeline includes differentiated assets like IPH4502, lacutamab, and monalizumab, and it maintains collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca.
Key Highlights
- Innate Pharma to participate in a panel discussion at the BTIG Virtual Biotechnology Conference.
- Panel discussion titled 'Changing Treatment Landscape in Bladder Cancer'.
- The event is scheduled for July 28, 2026, at 10:30 a.m. EDT / 4:30 p.m. CEST.
- Innate Pharma is a clinical-stage biotechnology company focused on cancer immunotherapies.
- Key pipeline assets include IPH4502, lacutamab, and monalizumab.
- The company has collaborations with Sanofi and AstraZeneca.
Price Impact
More from IPHA